|
| |
Pharmacyclics IncorporatedPharmacyclics, Inc. is a pharmaceutical company developing energy-potentiating drugs to improve radiation therapy andchemotherapy of cancer, and to enable or improve the photodynamic therapy of certain cancers, atherosclerotic cardiovascular disease and retinal diseases. The Company's products are ring-shaped small molecules, called "texaphyrins,"
which are patented agents derived from Pharmacyclics' versatile technology platform for designing and synthesizing energy-potentiating drugs. These texaphyrins localize in cancer cells and atherosclerotic plaque, where they can be activated by forms of energy, including X-ray, chemical and light, to selectively eliminate diseased tissue. The Company's lead texaphyrin-based product candidates are Gd-Tex, a gadolinium texaphyrin molecule being developed for use as a radiation sensitizer (initially in the treatment of brain metastases) and chemosensitizer; LUTRIN(TM) photosensitizer, a lutetium texaphyrin molecule being developed as a photosensitizer for use in photodynamic therapy of cancer; ANTRIN(TM) photosensitizer, a lutetium texaphyrin molecule being developed as a photosensitizer for use in the photoangioplasty of atherosclerosis; and OPTRIN(TM) photosensitizer, a lutetium texaphyrin molecule being developed as a photosensitizer for use in photodynamic therapy of age related macular degeneration (ARMD).
| Contact Details: |
| 995 East Arques Avenue |
| Sunnyvale |
| CA |
| 94086-4521 |
| United States of America |
| Tel: | 408 774 0330 |
| Fax: | 408 774 0340 |
| Email: | info@pcyc.com |
| WWW: | www.pcyc.com/
|
|
Loading...
|
Recent Publications by Pharmacyclics Incorporated: |  |
Isoform-specific histone deacetylase inhibitors: the next step?
Histone deacetylases (HDACs) have emerged as attractive drug targets,... | 24th June, 2009
| Department of Cancer Biology, Pharmacyclics, Inc, Sunnyvale, CA 94085,
| Cancer Lett. 2009 Aug 8;280(2):211-21. Epub 2009 Mar 16.
DOI Direct Link |
Synthesis and anticancer properties of water-soluble zinc ionophores.
Several water-solubilized versions of the zinc ionophore... | 6th August, 2008
| Pharmacyclics, Inc,
| Cancer Res. 2008 Jul 1;68(13):5318-25.
DOI Direct Link |
A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas.
We have developed a potent, histone deacetylase 8 (HDAC8)-specific... | 24th June, 2008
| Department of Cancer Biology, Pharmacyclics Inc., Sunnyvale, CA 94085,
| Leukemia. 2008 May;22(5):1026-34. Epub 2008 Feb 7.
DOI Direct Link |
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination.
Histone deacetylase (HDAC) inhibitors such as the phenyl hydroxamic acid... | 19th January, 2008
| Pharmacyclics, Inc., Sunnyvale, CA 94085-4521, USA.
| Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19482-7. Epub 2007 Nov 27.
DOI Direct Link |
Validation and use of three complementary analytical methods (LC-FLS, LC-MS/MS and ICP-MS) to evaluate the pharmacokinetics, biodistribution and stability of motexafin gadolinium in plasma and tissues.
Liquid chromatography-fluorescence (LC-FLS), liquid chromatography-tandem... | 9th May, 2007
| Pharmacyclics, Inc., 995 E. Arques Avenue, Sunnyvale, CA 94085, USA.
| Anal Bioanal Chem. 2006 May;385(2):345-56. Epub 2006 Apr 12.
DOI Direct Link |
→View more Pharmacyclics Incorporated research publications. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 345 times since April 2007, the link to the organisation's website has been followed 49 times Recent Search Terms used to find this page: pharmacyclics | . Search for more companies in Sunnyvale Search for more companies in CA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Pharmacyclics Incorporated |
